Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Rojas, Camilo ^a   Stathis, Marigo ^a   Polydefkis, Michael ^a   Rudek, Michelle A ^a   Zhao, Ming ^a   Ebenezer, Gigi J ^a   Slusher, Barbara S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYL HYDROLASE; 2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; 2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID; BIOLOGICAL MARKER; CARBOXYPEPTIDASE; ORGANOPHOSPHORUS COMPOUND;

ANIMAL TISSUE; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FOREFOOT; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PERIPHERAL NERVE; PHARMACODYNAMICS; RAT; SKIN BIOPSY; ANIMAL; BIOPSY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; SCIATIC NERVE; SKIN; TIME; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; BIOPSY; CARBOXYPEPTIDASES; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MASS SPECTROMETRY; ORGANOPHOSPHORUS COMPOUNDS; RATS; RATS, WISTAR; SCIATIC NERVE; SKIN; TIME FACTORS;

EID: 79952323297     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-27     Document Type: Article

References (27)

1. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999, 81:163-221. 10.1016/S0163-7258(98)00042-4, 10334661.
2. Neale JH, Olszewski RT, Gehl LM, Wroblewska B, Bzdega T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci 2005, 26:477-484.
3. Robinson MB, Blakely RD, Couto R, Coyle JT. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 1987, 262:14498-14506.
4. Berger UV, Carter RE, McKee M, Coyle JT. N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system. J Neurocytol 1995, 24:99-109. 10.1007/BF01181553, 7745446.
5. Carozzi VA, Canta A, Oggioni N, Ceresa C, Marmiroli P, Konvalinka J, Zoia C, Bossi M, Ferrarese C, Tredici G, Cavaletti G. Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system. J Anat 2008, 213:539-546. 2667548, 19014361.
6. Cassidy M, Neale JH. N-acetylaspartylglutamate catabolism is achieved by an enzyme on the cell surface of neurons and glia. Neuropeptides 1993, 24:271-278. 10.1016/0143-4179(93)90015-3, 8100987.
7. Bzdega T, Crowe SL, Ramadan ER, Sciarretta KH, Olszewski RT, Ojeifo OA, Rafalski VA, Wroblewska B, Neale JH. The cloning and characterization of a second brain enzyme with NAAG peptidase activity. J Neurochem 2004, 89:627-635. 10.1111/j.1471-4159.2004.02361.x, 15086519.
8. Bacich DJ, Wozniak KM, Lu XC, O'Keefe DS, Callizot N, Heston WD, Slusher BS. Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J Neurochem 2005, 95:314-323. 10.1111/j.1471-4159.2005.03361.x, 16190866.
9. Carozzi VA, Chiorazzi A, Canta A, Lapidus RG, Slusher BS, Wozniak KM, Cavaletti G. Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 2009, 17:380-391. 10.1007/s12640-009-9114-1, 19763734.
10. Chen SR, Wozniak KM, Slusher BS, Pan HL. Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther 2002, 300:662-667. 10.1124/jpet.300.2.662, 11805230.
11. Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ, Monti AL, Roos RP. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA 2003, 100:9554-9559. 10.1073/pnas.1530168100, 170956, 12876198.
12. Nagel J, Belozertseva I, Greco S, Kashkin V, Malyshkin A, Jirgensons A, Shekunova E, Eilbacher B, Bespalov A, Danysz W. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology 2006, 51:1163-1171. 10.1016/j.neuropharm.2006.07.018, 16926034.
13. Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XC, Tortella FC, Wozniak KM, Yudkoff M, Potter BM, Jackson PF. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999, 5:1396-1402. 10.1038/70971, 10581082.
14. Xi ZX, Li X, Peng XQ, Li J, Chun L, Gardner EL, Thomas AG, Slusher BS, Ashby CR. Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem 2010, 112:564-576. 10.1111/j.1471-4159.2009.06478.x, 2809121, 19895667.
15. Zhang W, Murakawa Y, Wozniak KM, Slusher B, Sima AA. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 2006, 247:217-223. 10.1016/j.jns.2006.05.052, 16780883.
16. Zhang W, Slusher B, Murakawa Y, Wozniak KM, Tsukamoto T, Jackson PF, Sima AA. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci 2002, 194:21-28. 10.1016/S0022-510X(01)00670-0, 11809162.
17. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005, 4:1015-1026. 10.1038/nrd1903, 16341066.
18. van der Post JP, de Visser SJ, de Kam ML, Woelfler M, Hilt DC, Vornov J, Burak ES, Bortey E, Slusher BS, Limsakun T, Cohen AF, VanGerven JM. The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 2005, 60:128-136. 10.1111/j.1365-2125.2005.02396.x, 1884920, 16042665.
19. Thomas AG, Rojas CJ, Hill JR, Shaw M, Slusher BS. Bioanalysis of NAAG as a Marker of GCP II Inhibition. Anal Biochem 2010, 404:94-96. 10.1016/j.ab.2010.04.029, 20434427.
20. Slusher BS, Robinson MB, Tsai G, Simmons ML, Richards SS, Coyle JT. Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem 1990, 265:21297-21301.
21. Yamamoto T, Saito O, Aoe T, Bartolozzi A, Sarva J, Zhou J, Kozikowski A, Wroblewska B, Bzdega T, Neale JH. Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur J Neurosci 2007, 25:147-158. 10.1111/j.1460-9568.2006.05272.x, 17241276.
22. Cangro CB, Namboodiri MA, Sklar LA, Corigliano-Murphy A, Neale JH. Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. J Neurochem 1987, 49:1579-1588. 10.1111/j.1471-4159.1987.tb01030.x, 2889802.
23. Ebenezer GJ, McArthur JC, Thomas D, Murinson B, Hauer P, Polydefkis M, Griffin JW. Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain 2007, 130:2703-2714. 10.1093/brain/awm199, 17898011.
24. Griffin JW, McArthur JC, Polydefkis M. Assessment of cutaneous innervation by skin biopsies. Curr Opin Neurol 2001, 14:655-659. 10.1097/00019052-200110000-00016, 11562579.
25. Rojas C, Frazier ST, Flanary J, Slusher BS. Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem 2002, 310:50-54. 10.1016/S0003-2697(02)00286-5, 12413472.
26. Jackson PF, Slusher BS. Design of NAALADase inhibitors: a novel neuroprotective strategy. Curr Med Chem 2001, 8:949-957.
27. Rovenska M, Hlouchova K, Sacha P, Mlcochova P, Horak V, Zamecnik J, Barinka C, Konvalinka J. Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate 2008, 68:171-182. 10.1002/pros.20676, 18076021.